KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Capital Expenditures (2016 - 2025)

Gilead Sciences' Capital Expenditures history spans 17 years, with the latest figure at $205.0 million for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 39.46% year-over-year to $205.0 million; the TTM value through Dec 2025 reached $563.0 million, up 7.65%, while the annual FY2025 figure was $563.0 million, 7.65% up from the prior year.
  • Capital Expenditures reached $205.0 million in Q4 2025 per GILD's latest filing, up from $147.0 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $247.0 million in Q1 2022 to a low of $104.0 million in Q1 2025.
  • Average Capital Expenditures over 5 years is $148.9 million, with a median of $142.0 million recorded in 2022.
  • Peak YoY movement for Capital Expenditures: skyrocketed 49.7% in 2022, then plummeted 55.87% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at $156.0 million in 2021, then grew by 16.03% to $181.0 million in 2022, then grew by 18.78% to $215.0 million in 2023, then crashed by 31.63% to $147.0 million in 2024, then surged by 39.46% to $205.0 million in 2025.
  • Per Business Quant, the three most recent readings for GILD's Capital Expenditures are $205.0 million (Q4 2025), $147.0 million (Q3 2025), and $107.0 million (Q2 2025).